Comparative Pharmacology
Head-to-head clinical analysis: ALPRAZOLAM versus NAYZILAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPRAZOLAM versus NAYZILAM.
ALPRAZOLAM vs NAYZILAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
Nayzilam (midazolam) is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal activity.
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
5 mg intranasally as a single dose; may repeat once after 10 minutes if needed. Maximum 10 mg per episode.
None Documented
None Documented
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Clinical Note
moderateAlprazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Alprazolam is combined with Fluticasone propionate."
Clinical Note
moderateAlprazolam + Haloperidol
"The risk or severity of adverse effects can be increased when Alprazolam is combined with Haloperidol."
Clinical Note
moderateAlprazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Alprazolam."
Clinical Note
moderateAlprazolam + Erythromycin
Terminal elimination half-life of midazolam is 1.5–2.5 hours, but for NAYZILAM (midazolam nasal spray) the effective half-life for anticonvulsant effect is approximately 2–3 hours due to prolonged absorption; clinical context: used for seizure clusters, duration of effect may persist for 4–6 hours.
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
Renal excretion as metabolites (primarily glucuronide conjugates) and unchanged drug; approximately 15% recovered in urine as unchanged midazolam, with the remainder as metabolites; <1% excreted in feces via biliary elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The serum concentration of Erythromycin can be increased when it is combined with Alprazolam."